Market Place
Sourcing Support
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
01 Aug 2024 //
GLOBENEWSWIRE
Greenwich LifeSciences Set to Join Russell 2000 Index Again
26 Jun 2024 //
GLOBENEWSWIRE
Greenwich LifeSciences Announces $2.5 Million Private Placement
14 Jun 2024 //
GLOBENEWSWIRE
Greenwich Life Extends Lock-up of Directors and Officers to June 30, 2025
13 Mar 2024 //
GLOBENEWSWIRE
Greenwich LifeSciences Partners with GEICAM in Spain
12 Mar 2024 //
GLOBENEWSWIRE
Greenwich Flamingo-01 Phase III Trial Approved to Expand into EU Countries
27 Feb 2024 //
GLOBENEWSWIRE
Greenwich Life Flamingo-01 Manufacturing & Protocol Accepted by EU
22 Feb 2024 //
GLOBENEWSWIRE
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
14 Feb 2024 //
GLOBENEWSWIRE
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
21 Nov 2023 //
GLOBENEWSWIRE
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
01 Dec 2022 //
BUSINESSWIRE
Greenwich Management`s Discussion of Financial Condition
14 Nov 2022 //
MARKETSCREENER
Greenwich begins Phase III trial of immunotherapy for breast cancer
12 Aug 2022 //
CLINICALTRIALSARENA
Greenwich Announces Activation of Clinical Sites and Phase III Clinical Trial
11 Aug 2022 //
BUSINESSWIRE
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
03 Aug 2022 //
BUSINESSWIRE
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
28 Jul 2022 //
BUSINESSWIRE
FDA lifts hold on Greenwich as it moves ahead with immunotherapy drug candidate
13 Jul 2022 //
ENDPTS
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
11 Jul 2022 //
BUSINESSWIRE
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 22,535 Shares
27 Jun 2022 //
MARKETBEAT
Greenwich LifeSciences Shares Rise 11% After CEO Increases Stake
03 Jun 2022 //
MORNINGSTAR
Greenwich LifeSciences to Resume Stock Repurchase Program
23 May 2022 //
BUSINESSWIRE
Greenwich LifeSciences Provides Updates on Upcoming PIII Trial & ASCO Meeting
23 May 2022 //
BUSINESSWIRE
Greenwich LifeSciences to Participate in Upcoming International Conferences
20 Apr 2022 //
BUSINESSWIRE
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022
19 Apr 2022 //
BUSINESSWIRE
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial
03 Mar 2022 //
BUSINESSWIRE
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
03 Feb 2022 //
BUSINESSWIRE
Greenwich Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
01 Feb 2022 //
BUSINESSWIRE
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10M
24 Jan 2022 //
BUSINESSWIRE
Greenwich to present 5 Year Data for GP2 Phase IIb Clinical Trial
09 Dec 2021 //
BUSINESSWIRE
Greenwich LifeSciences Provides Update on Upcoming Phase III Trial, FLAMINGO-01
10 Nov 2021 //
BUSINESSWIRE
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
09 Nov 2021 //
BUSINESSWIRE
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
09 Sep 2021 //
BIOSPACE
Greenwich LifeSciences Statement of Changes in Beneficial Ownership
08 Sep 2021 //
PRESS RELEASE
Greenwich LifeSciences to Participate in Citi’s Biopharma Virtual Conference
07 Sep 2021 //
BUSINESSWIRE
Greenwich LifeSciences Set to Join Russell 2000® Index
08 Jun 2021 //
BUSINESSWIRE
Greenwich Publishes Additional Positive Safety Data from GP2 Phase IIb Trial
07 Jun 2021 //
BUSINESSWIRE
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial
14 Apr 2021 //
BUSINESSWIRE
Greenwich Announces Update of GP2 PhaseII Trial Design at the 2021 AACR
14 Apr 2021 //
BUSINESSWIRE
Greenwich Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinica
09 Apr 2021 //
BIOSPACE
Greenwich LifeSciences CEO to Participate on Cancer Panel
22 Mar 2021 //
BUSINESSWIRE
Greenwich Updates 2021 Timeline & Announces Two Upcoming Presentations
11 Mar 2021 //
BIOSPACE
Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
10 Mar 2021 //
BUSINESSWIRE
Greenwich to Present at Multiple Investor Conferences, Including H.C.
02 Mar 2021 //
BUSINESSWIRE
Greenwich LifeSciences Announces Acceptance of Two Abstracts
25 Feb 2021 //
BUSINESSWIRE
Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming
24 Feb 2021 //
BUSINESSWIRE
Greenwich Announces Exercise and Closing of Underwriter’s Over-Allotment Option
29 Jan 2021 //
BUSINESSWIRE
Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Stock
22 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences, Inc. Announces Closing of Public Offering
22 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus
15 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus
15 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces Poster on Its GP2 Phase III Trial Design
11 Dec 2020 //
BUSINESSWIRE
Greenwich Announces Poster Presentation on Its GP2 Ph III Trial
11 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2
09 Dec 2020 //
BUSINESSWIRE
Greenwich Announces Poster Presentation of Five Year Data for GP2 Phase IIb
09 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces New Manufacturing Agreement
03 Dec 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces 2nd Publication and Second Poster of Phase III
23 Nov 2020 //
BUSINESSWIRE
Greenwich LifeSciences Announces Publication of Positive Ph IIb Trial
18 Nov 2020 //
BUSINESSWIRE
